BioSpace News Archive

According to the Centers for Disease Control and Prevention, fluoridated water reduces tooth decay by about 25%.

Physical activity together with relative humidity and temperature decides the amount of thermal insulation needed by the clothing system.

Growing inclination toward minimally invasive surgeries together with increased prevalence of chronic conditions are likely to emerge as growth factors for the for the global monopolar electrosurgery instrument market over the period of projection, 2019 to 2029.

Alligator Bioscience announced that it has submitted a CTA application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting antibody mitazalimab.

United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).

CB Scientific. Inc. (OTC:CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT) in Thailan

Specialty Pharma Company Selling Ecoza® (econazole nitrate) topical foam, 1%, Recedo® Topical Gel, Neosalus® Cream, Neosalus® Foam, and Neocera® Advanced Cream Is Focused on Patient Outcomes

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight; ultraviolet A light catheter technology.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (“PRV”) to United Therapeutics Corporation (Nasdaq: UTHR), based on an agreed valuation of $105 million